Oral submucous fibrosis and heterogeneity in outcome measures: a critical viewpoint
2021; Future Medicine; Volume: 17; Issue: 17 Linguagem: Inglês
10.2217/fon-2021-0287
ISSN1744-8301
AutoresSachin C. Sarode, Shailesh Gondivkar, Amol Gadbail, Gargi S. Sarode, Monal Yuwanati,
Tópico(s)Oral and Maxillofacial Pathology
ResumoFuture OncologyVol. 17, No. 17 EditorialOral submucous fibrosis and heterogeneity in outcome measures: a critical viewpointSachin C Sarode, Shailesh Gondivkar, Amol Gadbail, Gargi S Sarode & Monal YuwanatiSachin C Sarode *Author for correspondence: Tel.: +91 992 249 1465; E-mail Address: drsachinsarode@gmail.comhttps://orcid.org/0000-0003-1856-0957Department of Oral Pathology & Microbiology, Dr. D.Y. Patil Dental College & Hospital, Dr. D.Y. Patil Vidyapeeth, Sant-Tukaram Nagar, Pimpri, Pune, 411018, Maharashtra, India, Shailesh GondivkarDepartment of Oral Medicine & Radiology, Government Dental College & Hospital, Nagpur, 440003, Maharashtra, India, Amol GadbailDepartment of Dentistry, Indira Gandhi Government Medical College & Hospital, Nagpur, 440018, Maharashtra, India, Gargi S Sarode https://orcid.org/0000-0003-4628-8866Department of Oral Pathology & Microbiology, Dr. D.Y. Patil Dental College & Hospital, Dr. D.Y. Patil Vidyapeeth, Sant-Tukaram Nagar, Pimpri, Pune, 411018, Maharashtra, India & Monal Yuwanati https://orcid.org/0000-0001-9233-8292Department of Oral Pathology & Microbiology, Saveetha Dental College & Hospitals, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai, 600077, IndiaPublished Online:16 Apr 2021https://doi.org/10.2217/fon-2021-0287AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: measurement methodsoral submucous fibrosisoutcome measuresPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. doi: 10.1111/odi.13704 (2020) (Epub ahead of print).Crossref, Google Scholar2. International Agency for Research on Cancer. Betel-quidand areca-nut chewing and some areca-nut derived nitrosamines. In: IARC monographs on the identification of carcinogenic risks to humans: Volume 85. IARC, Lyons, France (2004).Google Scholar3. International Agency for Research on Cancer. Acrolein, crotonaldehyde, and Arecoline In: IARC monographs on the identification of carcinogenic risks to humans: Volume 128. IARC, Lyon, France, 29 October–13 November 2020.Google Scholar4. Gondivkar SM, Bhowate RR, Gadbail AR et al. Development and validation of oral health-related quality of life measure in oral submucous fibrosis. Oral Dis. 24(6), 1020–1028 (2018).Crossref, Medline, CAS, Google Scholar5. Devi P, Singh I, Setru R et al. Evaluation of hearing deficit in patients with oral submucous fibrosis. J. Oral Sci. 57(2), 109–113 (2015).Crossref, Medline, CAS, Google Scholar6. Kujan O, Mello FW, Warnakulasuriya S. Malignant transformation of oral submucous fibrosis: a systematic review and meta-analysis. Oral Dis. doi: 10.1111/odi.13727 (2020) (Epub ahead of print).Crossref, Google Scholar7. Gadbail AR, Choudhary M, Gawande M et al. Oral squamous cell carcinoma in the background of oral submucous fibrosis is a clinicopathological entity with better prognosis. J. Oral Pathol. Med. 46, 448–453 (2017).Crossref, Medline, CAS, Google Scholar8. Chole RH, Gondivkar SM, Gadbail AR et al. Review of drug treatment of oral submucous fibrosis. Oral Oncol. 48(5), 393–398 (2012).Crossref, Medline, CAS, Google Scholar9. Sarode GS, Sarode SC, Patil S. Medicinal treatment of oral submucous fibrosis: why is research not still translated into actual practice? OralOncol. 115, 105099 (2020) (Epub ahead of print).Google Scholar10. Datarkar A, Akare A, Tayal S. Efficacy of prednisolone mouthwash in management of grade III oral submucous fibrosis: a newer drug regimen. J. Maxillofac. Oral Surg. 19(4), 532–538 (2020).Crossref, Medline, Google Scholar11. Piyush P, Mahajan A, Singh K et al. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: a randomized controlled trial. Oral Dis. 25(1), 73–79 (2019).Crossref, Medline, Google Scholar12. Saran G, Umapathy D, Misra N et al. A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: a randomized clinical trial. Indian J. Dent. Res. 29(3), 303–312 (2018).Crossref, Medline, Google Scholar13. Anuradha A, Patil B, Asha VR. Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis – a clinical study. J. Oral Pathol. Med. 46(1), 50–55 (2017).Crossref, Medline, Google Scholar14. Pipalia PR, Annigeri RG, Mehta R. Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis-a double-blind, ran-domized preliminary study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 122(6), 705–712 (2016).Crossref, Medline, Google Scholar15. Veedu RA, Balan A, Sankar SP. A randomized double-blind, multiple-arm trial comparing the efficacy of submucosal injections of hyaluronidase, dexamethasone, and combination of dexamethasone and hyaluronidase in the management of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 120(5), 588–593 (2015).Crossref, Medline, Google Scholar16. Biswas G, Anup N, Kumawat H. Efficacy of lycopene in the management of oral submucous fibrosis – a randomized clinical trial. Ind. J. Public Health Res. Dev. 6(3), 33–37 (2015).Crossref, Google Scholar17. Alam S, Ali I, Giri KY et al. Efficacy of aloe vera gel as an adjuvant treatment of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 116(6), 717–724 (2013).Crossref, Medline, Google Scholar18. Jiang XW, Zhang Y, Yang SK et al. Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115(3), 339–344 (2013).Crossref, Medline, Google Scholar19. Singh M, Niranjan HS, Mehrotra R et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J. Med. Res. 131, 665–669 (2010).Medline, CAS, Google Scholar20. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103(2), 207–213 (2007).Crossref, Medline, Google Scholar21. Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J. Dent. Res. 17(4), 190–198 (2006).Crossref, Medline, CAS, Google Scholar22. Rimal J, Shrestha A. Validation of Nepalese oral health impact profile14 and assessment of its impact in patients with oral submucous fibrosis in Nepal. J. Nepal. Health Res. Counc. 13(29), 43–49 (2015).Medline, CAS, Google Scholar23. Chole R, Patil R. Assessment of the quality of life and performance status in patients with oral submucous fibrosis in central India. Clujul. Med. 91, 203–208 (2018).Medline, Google Scholar24. Cano SJ, Klassen A, Pusic AL. The science behind quality-of-life measurement: a primer for plastic surgeons. Plast. Reconstr. Surg. 123(3), 98e–106e (2009).Crossref, Medline, Google Scholar25. Gondivkar SM, Gadbail AR, Gondivkar RS et al. Impact of oral potentially malignant disorders on quality of life: a systematic review. Future Oncol. 14(10), 995–1010 (2018).Link, CAS, Google Scholar26. Raja JV, Rai P, Kumar NC et al. Psychiatric morbidity among patients with oral submucous fibrosis: a controlled study. Oral Health Dent. Manag. 12(2), 85–94 (2013).Medline, Google Scholar27. Rana M, Gellrich NC, Rana M. Comparison of health-related quality of life of patients with different precancer and oral cancer stages. Clin. Oral Investig. 19(2), 481–488 (2015).Crossref, Medline, Google Scholar28. Gondivkar SM, Bhowate RR, Gadbail AR et al. Assessment of oral health-related quality of life instruments for oral submucous fibrosis: a systematic review using the consensus-based standards for the selection of health measurement instruments (COSMIN) checklist. Oral Oncology 93, 39–45 (2019).Crossref, Medline, Google Scholar29. Taylor J, Walsh T, Worthington H et al. Cochrane and the COMET initiative: developing the evidence base in oral medicine. Br. Dent. J. 223, 729–732 (2017).Crossref, Medline, CAS, Google Scholar30. Yan YR, Hua F, He MJ et al. Heterogeneity of outcome measures used in randomized controlled trials for the treatment of oral lichen planus: a methodological study. J. Evid. Based Dent. Pract. 20(3), 101468 (2020).Crossref, Medline, Google Scholar31. Boers M, Kirwan JR, Wells G et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J. Clin. Epidemiol. 67, 745–753 (2014).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByHybrid oral potentially malignant disorder: A neglected fact in oral submucous fibrosisOral Oncology, Vol. 121 Vol. 17, No. 17 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 94 times History Received 6 March 2021 Accepted 31 March 2021 Published online 16 April 2021 Published in print June 2021 Information© 2021 Future Medicine LtdKeywordsmeasurement methodsoral submucous fibrosisoutcome measuresFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)